Genentech and AC Immune’s Semorinemab Flounders in P-II TAURIEL Study for Early Alzheimer’s Disease

 Genentech and AC Immune’s Semorinemab Flounders in P-II TAURIEL Study for Early Alzheimer’s Disease

Shots:

  • The P-II TAURIEL study involves assessing of semorinemab vs PBO in 457 patients with early AD across 97 sites
  • Genentech divulges that the P-II TAURIEL study did not meet its co-1EPs of efficacy (reducing decline on CDR-SB) but meets its 1EPs of safety while the two 2EPs (ADAS-Cog13 & ADCS-ADL) was not met, results will be presented at the upcoming medical congress
  • The second P-II LAURIET study of semorinemab in patients with moderate AD remains ongoing. Additionally, IND enabling studies are ongoing for first-in-class therapeutic candidates targeting TDP-43 and alpha-synuclein

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Fortune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post